Leucovorin

Generic Name: Leucovorin

Brand Names: EnBrace HR, EnLyte, Lederle Leucovorin

Drug Type: Small Molecule

Chemical Formula: C_₂₀H_₂₃N_₇O_₇

CAS Number: 58-05-9

Unique Ingredient Identifier: Q573I9DVLP

Background: Folinic Acid (also known as 5-formyl tetrahydrofolic acid or leucovorin) is the 5-formyl derivative of tetrahydrofolic acid, a necessary co-factor in the body. Commercially available leucovorin is composed of a 1:1 racemic mixture of the dextrorotary and levorotary isomers, while levoleucovorin contains only the pharmacologically active levo-isomer. In vitro...

Indication: For the treatment of osteosarcoma (after high dose methotrexate therapy). Used to diminish the toxicity and counteract the effects of impaired methotrexate elimination and of inadvertent overdosages of folic acid antagonists, and to treat megaloblastic anemias due to folic acid deficiency. Also used in combination with 5-fluorouracil to prolong survival in t...

Associated Conditions: Advanced Colorectal Cancer, Advanced Esophageal Cancers, Anemia of Pregnancy, Bladder Cancer, Folate and iron deficiency, Folate deficiency, Folic acid antagonist overdose, Iron Deficiency (ID), Macrocytic anemia, Megaloblastic anemia, Pancreatic Metastatic Cancer, Postpartum Anemia, Stage IV Gastric Cancer, Hypochromic anemia, Methotrexate toxicity, Normochromic anemia, Pyrimethamine hematologic toxicity

Associated Therapies: -

Clinical Trials

NBTXR3, Chemotherapy, and Radiation Therapy for the Treatment of Esophageal Cancer

Phase 1

Recruiting

Conditions: Pathologic Stage II Esophageal Adenocarcinoma AJCC v8
Pathologic Stage IIIB Esophageal Adenocarcinoma AJCC v8
Clinical Stage II Esophageal Adenocarcinoma AJCC v8
Clinical Stage IIB Esophageal Adenocarcinoma AJCC v8
Thoracic Esophagus Adenocarcinoma
Cervical Esophagus Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
Pathologic Stage IIA Esophageal Adenocarcinoma AJCC v8
Pathologic Stage III Esophageal Adenocarcinoma AJCC v8
Pathologic Stage IIB Esophageal Adenocarcinoma AJCC v8

Interventions: Drug: Capecitabine
Drug: Carboplatin
Drug: Docetaxel
Drug: Fluorouracil
Other: Hafnium Oxide-containing Nanoparticles NBTXR3
Radiation: Intensity-Modulated Radiation Therapy
Drug: Leucovorin
Drug: Oxaliplatin
Drug: Paclitaxel

First Posted Date: 2020-11-04

Last Posted Date: 2024-11-11

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 24

Registration Number: NCT04615013

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer

Phase 3

Active, not recruiting

Conditions: Neoplasms

Interventions: Drug: Encorafenib
Drug: Cetuximab
Drug: Irinotecan
Drug: Oxaliplatin
Drug: Leucovorin
Drug: 5-FU
Drug: Capecitabine
Drug: Bevacizumab

First Posted Date: 2020-10-29

Last Posted Date: 2024-12-17

Lead Sponsor: Pfizer

Target Recruit Count: 816

Registration Number: NCT04607421

Locations: 🇺🇸
LAC & USC Medical Center, Los Angeles, California, United States
🇺🇸
Cedars- Sinai Medical Center, Los Angeles, California, United States
🇺🇸
Investigational Drug Service, The Ohio State University Wexner Medical Center, Columbus, Ohio, United States

and more 378 locations

Oncological Benefits of Pressured Intraperitoneal Aerosol Chemotherapy (PIPAC) in Patients With T3-4 Gastric Cancer Cyt-

Not Applicable

Recruiting

Conditions: Peritoneal Carcinomatosis
Gastric Cancer

Interventions: Procedure: Staging laparoscopy
Drug: 5-Fluorouracil
Drug: Leucovorin
Drug: Oxaliplatin
Drug: Docetaxel
Procedure: Radical surgery
Procedure: PIPAC
Drug: Adjuvant chemotherapy

First Posted Date: 2020-10-22

Last Posted Date: 2020-11-25

Lead Sponsor: St. Petersburg State Pavlov Medical University

Target Recruit Count: 304

Registration Number: NCT04595929

Locations: 🇷🇺
First Pavlov State Medical University of St. Petersburg, Saint-Petersburg, Russian Federation

Biweekly Actinomycin-D Treatment or Multi-day Methotrexate Protocol in Low-risk Gestational Trophoblastic Neoplasia

Not Applicable

Recruiting

Conditions: Gestational Trophoblastic Tumor
Gestational Trophoblastic Neoplasia
Stage III Gestational Trophoblastic Tumor
Stage II Gestational Trophoblastic Tumor
Choriocarcinoma
Stage I Gestational Trophoblastic Tumor
Invasive Mole

Interventions: Drug: Methotrexate
Drug: Dactinomycin
Drug: Leucovorin

First Posted Date: 2020-09-24

Last Posted Date: 2023-09-06

Lead Sponsor: xiang yang

Target Recruit Count: 228

Registration Number: NCT04562558

Locations: 🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China

Immunoscore as Decision Guidance for Adjuvant Chemotherapy in Colon Cancer

Phase 3

Not yet recruiting

Conditions: Colon Cancer Stage III

Interventions: Drug: Capecitabine
Drug: Oxaliplatin
Drug: Fluorouracil
Drug: Leucovorin
Device: Immunoscore® assay
Other: Physical exercise

First Posted Date: 2020-07-27

Last Posted Date: 2024-03-15

Lead Sponsor: Johannes Laengle, MD, PhD

Target Recruit Count: 1638

Registration Number: NCT04488159

Locations: 🇦🇹
Medical University of Vienna, Vienna, Austria

New and Emerging Therapies for the Treatment of Resectable, Borderline Resectable, or Locally Advanced Pancreatic Cancer, PIONEER-Panc Study

Phase 2

Active, not recruiting

Conditions: Borderline Resectable Pancreatic Adenocarcinoma
Locally Advanced Pancreatic Ductal Adenocarcinoma
Resectable Pancreatic Ductal Adenocarcinoma

Interventions: Drug: Fluorouracil
Drug: Cisplatin
Drug: Irinotecan
Drug: Leucovorin
Drug: Gemcitabine
Drug: Oxaliplatin
Radiation: Radiation Therapy
Drug: Nab-paclitaxel

First Posted Date: 2020-07-22

Last Posted Date: 2024-10-28

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 105

Registration Number: NCT04481204

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Pembrolizumab Plus Chemotherapy in 1st Line Treatment of Pancreatic Cancer

Phase 2

Active, not recruiting

Conditions: Pancreatic Cancer
Chemotherapy Effect

Interventions: Drug: Pembrolizumab
Drug: Gemcitabine
Drug: Nab-paclitaxel
Drug: Oxaliplatin
Drug: Leucovorin
Drug: Irinotecan
Drug: 5FU

First Posted Date: 2020-06-25

Last Posted Date: 2024-04-19

Lead Sponsor: Seoul National University Hospital

Target Recruit Count: 77

Registration Number: NCT04447092

Locations: 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of

HIPEC + FLOT vs. FLOT Alone in Patients With Gastric Cancer and GEJ (PREVENT)

Phase 3

Recruiting

Conditions: Gastric Cancer
Gastroesophageal Junction Adenocarcinoma

Interventions: Drug: 5-Fluorouracil
Drug: Leucovorin
Drug: Oxaliplatin
Drug: Docetaxel
Drug: Cisplatin

First Posted Date: 2020-06-25

Last Posted Date: 2024-11-12

Lead Sponsor: Krankenhaus Nordwest

Target Recruit Count: 200

Registration Number: NCT04447352

Locations: 🇩🇪
Uniklinik RWTH Aachen, AöR, Medizinische Klinik III, Studienzentrum Viszeralmedizin, Aachen, Germany
🇩🇪
Institute of Clinical Cancer Research (IKF), UCT - University Cancer Center, Frankfurt, Germany, Frankfurt, Germany
🇩🇪
Universitätsklinikum, Klinik und Poliklinik für Viszeral-, Thorax- und Gefäßchirurgie, Dresden, Germany

and more 12 locations